Figure S8 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Figure S8: Acute toxicity study of the [225Ac]DOTA-YS5 in nude mice (n=5). A The body weights of mice injected with [225Ac]DOTA-YS5 showed no significant change in treatment groups over the 15 days study period. B&C: Liver and kidney function tests (B) and blood parameters (C) show no significant changes for saline vs. treated groups indicating the short-term safety of [225Ac]DOTA-YS5.